Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Public trust is key to a successful immunisation programme, writes Samantha Vanderslott in a piece for The Conversation.

Vaccination © Image by Angelo Esslinger from Pixabay

If you have been following the media coverage of the new vaccines in development for COVID-19, it will be clear that the stakes are high. Very few vaccine trials in history have attracted so much attention, perhaps since polio in the mid-20th century.

A now largely forgotten chapter, summer polio outbreaks invoked terror in parents. Today, restrictions on gatherings and movement in the efforts to control COVID-19 have been a huge strain on society, but in the 1950s, parents locked their children in stifling hot buildings during the summer with windows sealed shut because they were terrified polio would somehow seep through the cracks in the wall.

The development of the polio vaccine in the US in 1955 was a moment of global celebration. Reaching that point involved millions of citizens raising funds to develop the vaccine, political goodwill by the bucket-load and a driven public-private scientific collaboration, with scientist Jonas Salk at the helm. Children across the US were enlisted in one of the largest clinical trials in history.

Read the full article on The Conversation website, written by .

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

COVID-19 Vaccinology

University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.

Oxford University breakthrough on global COVID-19 vaccine

COVID-19 Vaccinology

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

Oxford coronavirus vaccine produces strong immune response in older adults

COVID-19 Vaccinology

The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.

SIMON Says…

Vaccinology

Researchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.

There is now clear data on Covid-19 and children: it should be safe to reopen English schools

Parents & Carers Vaccinology

In an opinion piece for The Guardian, Professor Matthew Snape discusses the initial results of his team's antibody study in the context of coronavirus risk to school children.

Typhoid vaccine project wins Vice-Chancellor award

Awards & Appointments Vaccinology

Congratulations to Professor Andrew Pollard who is the Winner of the Policy Engagement category in the Vice-Chancellor Innovation Awards 2020 for his work on Global policy on typhoid vaccines through research at Oxford!